Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + ADT in regional prostate cancer
NCT05574712Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Rate of near pathological complete response at 12 weeks. Planned start Jan 2024; status: withdrawn.
02
Drugs
belzutifan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05574712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574712.